Located in Europe (France) and North America (Billerica, MA), ImaBiotech offers End-to-end services from drug discovery to drug development. Using ImaLink platform, including unique imaging capabilities (GeoMx Nanostring, Ncounter Nanostring, Microdissection, Mass Spectrometry Imaging, Imaging mass cytometry and high multiplex IHC) and proprietary technologies (Multimaging™), ImaBiotech's experts can measure drug and biomarker distributions and concentrations at once, at single cell level within tissues (Spatial PK and SpatialOmics). This allows to obtain the full picture of drug accumulation and impact to the tissue microenvironment.
With the ImaLink platform, ImaBiotech offers a way to develop better and safer drugs from preclinical to clinical studies.
Imabiotech offers a fast solution to assess the target engagement of your drugs using a label free Quantitative MALDI imaging technology.
With this new services, you can screen and select drug candidates based on the co-distribution of drugs with the targets.
Target Engagement Studies
Biomarker are the key components for the evaluation of a disease or disease progression.
In order to satisfy efficacy or toxicity investigation, Imabiotech offers new approach of imaging to localize biomarkers of efficacy or toxicity in many different options:
In a single experiment, ImaBiotech evaluates drug distribution with biomarkers using Multimaging platform which combines different imaging techniques to discover and colocalize drugs and biomarkers together.
Histology shows consequences of toxicology pathology, while ImaBiotech identifies the cause with molecular histology.
Imaging services support your toxicity studies by identifying the specific compound distributions correlated to toxicity effects with Quantitative MALDI Imaging Mass Spectrometry, H&E staining and biomarker imaging techniques.
High Definition Toxicity Studies
In just a few days, ImaBiotech provides quantitative distributions of your lead compounds.
To select better drug candidate within a month, Imabiotech offers a combination of pharmacokinetics and pharmacodynamics studies using Quantitative MALDI imaging technology and its proprietary biomarkers databank.
This innovation in drug development process allows the distribution study of drug and metabolites with their read-out molecules. This provides a very fast evaluation drug candidate efficacy or toxicity.
With this new services, you can screen and select the best drug candidates based on the global distribution of drugs and metabolites with the level of biomarker changes.
Study Drug distribution at early stage to select best drug candidates : Screen your molecules, Faster, Better and Cheaper.
ImaBiotech developed a new way to screen your molecules. MALDI Imaging Mass Spectrometry technologies are perfectly suitable for drug candidates screening. Indeed quick study initiation allows obtaining the distribution comparison of different drug candidates at different time points per organ (whole-body section) or per histological region (single organ). This precious information allows to quickly identify or/and optimize a drug candidate.
ImaBiotech has not received any reviews.
ImaBiotech has not received any endorsements.